See today's BioWorld
To read the full story, subscribe or sign in.

Biosimilars Are at the Top of the FDA’s Shutdown Casualty List

Oct. 9, 2013
By Mari Serebrov
The first casualties are starting to come in from the partial shutdown at the FDA, with biosimilars at the top of the list.
BioWorld